The pharmacological and clinical aspects behind dose loading of biological disease modifying anti-rheumatic drugs (bDMARDs) in auto-immune rheumatic diseases (AIRDs): rationale and...

by Gerlienke E. Geurts-Voerman, Lise M. Verhoef, Bart J. F. van den Bemt, Alfons A. den Broeder
Published 2020-07-01

Impact of tapering targeted therapies (bDMARDs or JAKis) on the risk of serious infections and adverse events of special interest in patients with rheumatoid arthritis or spondyloa...

by D. Vinson, L. Molet-Benhamou, Y. Degboé, A. den Broeder, F. Ibrahim, C. Pontes, R. Westhovens, J. Závada, T. Pham, T. Barnetche, A. Constantin, A. Ruyssen-Witrand
Published 2020-04-01

Younger age and female gender are determinants of underestimated cardiovascular risk in rheumatoid arthritis patients: a prospective cohort study

by Daphne C. Rohrich, Eline H. M. van de Wetering, Alexander J. Rennings, Elke E. Arts, Inger L. Meek, Alfons A. den Broeder, Jaap Fransen, Calin D. Popa
Published 2021-01-01

Comparing methotrexate monotherapy with methotrexate plus leflunomide combination therapy in psoriatic arthritis: protocol of a randomized, placebo-controlled, double-blind clinica...

by Michelle L. M. Mulder, Johanna E. Vriezekolk, Nathan den Broeder, Elien A. M. Mahler, Philip S. Helliwell, Frank H. J. van den Hoogen, Alfons A. den Broeder, Mark H. Wenink
Published 2020-02-01

Ultra-low dose of rituximab in rheumatoid arthritis: study protocol for a randomised controlled trial

by Alfons A. den Broeder, Lise M. Verhoef, Jaap Fransen, Rogier Thurlings, Bart J. F. van den Bemt, Steven Teerenstra, Nadine Boers, Nathan den Broeder, Frank H. J. van den Hoogen
Published 2017-08-01

Using adalimumab serum concentration to choose a subsequent biological DMARD in rheumatoid arthritis patients failing adalimumab treatment (ADDORA-switch): study protocol for a ful...

by Maike H. M. Wientjes, Sadaf Atiqi, Gerrit Jan Wolbink, Michael T. Nurmohamed, Maarten Boers, Theo Rispens, Annick de Vries, Ronald F. van Vollenhoven, Bart J. F. van den Bemt, Alfons A. den Broeder
Published 2021-06-01

Dose reduction and withdrawal strategy for TNF-inhibitors in psoriatic arthritis and axial spondyloarthritis: design of a pragmatic open-label, randomised, non-inferiority trial

by Celia A. J. Michielsens, Nadine Boers, Nathan den Broeder, Mark H. Wenink, Aatke van der Maas, Elien A. M. Mahler, Michelle L. M. Mulder, Désirée van der Heijde, Frank H. J. van den Hoogen, Lise M. Verhoef, Alfons A. den Broeder
Published 2020-01-01

Validation study of existing gene expression signatures for anti-TNF treatment in patients with rheumatoid arthritis.

by Erik J M Toonen, Christian Gilissen, Barbara Franke, Wietske Kievit, Agnes M Eijsbouts, Alfons A den Broeder, Simon V van Reijmersdal, Joris A Veltman, Hans Scheffer, Timothy R D J Radstake, Piet L C M van Riel, Pilar Barrera, Marieke J H Coenen
Published 2012-01-01

Health Economic Consequences of a Tightly Controlled Dose Reduction Strategy for Adalimumab, Etanercept and Ustekinumab Compared with Standard Psoriasis Care: A Cost-utility Analys...

by Selma Atalay, Juul M.P.A. van den Reek, Marisol E. Otero, Marcellus D. Njoo, Johannes M. Mommers, Paul M. Ossenkoppele, Marjolein I. Koetsier, Maartje M. Berends, Peter C.M. van de Kerkhof, Hans M.M. Groenewoud, Alfons A. den Broeder, Elke M.G.J. de Jong, Wietske Kievit
Published 2020-12-01

Lengthening adalimumab dosing interval in quiescent Crohn’s disease patients: protocol for the pragmatic randomised non-inferiority LADI study

by J Jansen, L J T Smits, R W M Pauwels, W Kievit, D J de Jong, A C de Vries, F Hoentjen, C J van der Woude, A.A. van Bodegraven, A.G.L. Bodelier, P.J. Boekema, N. de Boer, P.C.J. ter Borg, A.A. den Broeder, I.A.M Gisbertz, F.M Jansen, S.V. Jansen, D.J. de Jong, W. Kievit, R.C.A. van Linschoten, M Löwenberg, M.W.M.D. Lutgens, R.C. Mallant-Hent, A.E. van der Meulen, B. Oldenburg, R.W.M. Pauwels, M Pierik, M.J.L. Romberg-Camps, T.E.H. Römkens, M.G.V.M. Russel, L.J.T. Smits, A.C.I.T.L. Tan, M.L. Verhulst, A.C. de Vries, R.L. West, F.H.J. Wolfhagen, C.J. van der Woude
Published 2020-05-01